...
首页> 外文期刊>Nature medicine >PI 3-kinase p110beta: a new target for antithrombotic therapy.
【24h】

PI 3-kinase p110beta: a new target for antithrombotic therapy.

机译:PI 3-激酶p110beta:抗血栓治疗的新靶标。

获取原文
获取原文并翻译 | 示例

摘要

Platelet activation at sites of vascular injury is essential for the arrest of bleeding; however, excessive platelet accumulation at regions of atherosclerotic plaque rupture can result in the development of arterial thrombi, precipitating diseases such as acute myocardial infarction and ischemic stroke. Rheological disturbances (high shear stress) have an important role in promoting arterial thrombosis by enhancing the adhesive and signaling function of platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa). In this study we have defined a key role for the Type Ia phosphoinositide 3-kinase (PI3K) p110beta isoform in regulating the formation and stability of integrin alpha(IIb)beta(3) adhesion bonds, necessary for shear activation of platelets. Isoform-selective PI3K p110beta inhibitors have been developed which prevent formation of stable integrin alpha(IIb)beta(3) adhesion contacts, leading to defective platelet thrombus formation. In vivo, these inhibitors eliminate occlusive thrombus formation but do notprolong bleeding time. These studies define PI3K p110beta as an important new target for antithrombotic therapy.
机译:血管损伤部位的血小板活化对于止血至关重要。然而,血小板过多在动脉粥样硬化斑块破裂区域积聚会导致动脉血栓形成,并加剧诸如急性心肌梗塞和缺血性中风等疾病。流变干扰(高剪切应力)通过增强血小板整合素α(IIb)beta(3)(GPIIb-IIIa)的黏附和信号传导功能,在促进动脉血栓形成中具有重要作用。在这项研究中,我们已经定义了Ia型磷酸肌醇3激酶(PI3K)p110beta亚型在调节整合素α(IIb)beta(3)粘附键的形成和稳定性中的关键作用,这对于血小板的剪切活化是必需的。已开发出同工型选择性PI3K p110beta抑制剂,可防止形成稳定的整联蛋白alpha(IIb)beta(3)粘附接触,从而导致血小板血栓形成不良。在体内,这些抑制剂可消除闭塞性血栓形成,但不会延长出血时间。这些研究将PI3K p110beta定义为抗血栓治疗的重要新靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号